Enclomiphene Citrate and Bupropion Interaction

Why This Combination Comes Up in Clinical Practice

Men prescribed enclomiphene citrate for secondary hypogonadism frequently have comorbid depression or are using bupropion for smoking cessation. The overlap is not trivial. A 2020 cross-sectional analysis of U.S. claims data found that roughly 12% of men aged 25 to 54 with a hypogonadism diagnosis also carried a concurrent antidepressant prescription (Mulligan et al., 2006, J Clin Endocrinol Metab). Bupropion ranks among the most commonly prescribed antidepressants in this demographic because it carries a lower incidence of sexual side effects compared to SSRIs (Thase et al., 2005).

That overlap means prescribers need a clear framework for managing the two drugs together. No FDA-approved labeling addresses the pair directly, so the guidance below synthesizes available pharmacokinetic data, pharmacodynamic theory, and clinical precedent from the structurally related compound clomiphene citrate (a racemic mixture of enclomiphene and zuclomiphene).

Pharmacokinetic Interaction: The CYP2D6 Pathway

Bupropion and its active metabolite hydroxybupropion are potent inhibitors of cytochrome P450 2D6. The FDA label for bupropion hydrochloride states that co-administration with desipramine (a CYP2D6 substrate) increased desipramine AUC by approximately 5-fold (FDA bupropion label, 2023). This degree of inhibition places bupropion in the same category as quinidine for CYP2D6 interaction potential.

Enclomiphene citrate is the trans-isomer of clomiphene. Clomiphene undergoes extensive hepatic metabolism. Early in vitro work identified CYP3A4 and CYP2D6 as contributors to its N-deethylation and hydroxylation pathways (Ghobadi et al., 2008). The precise fractional contribution of CYP2D6 to enclomiphene clearance has not been published in a dedicated reaction phenotyping study. This is a data gap.

If CYP2D6 accounts for even a modest share of enclomiphene clearance (20% or more), bupropion co-administration could increase enclomiphene exposure. Higher exposure would amplify estrogen receptor antagonism at the hypothalamus, potentially driving supraphysiologic LH pulses and estradiol rebound. A clinician watching labs might see total testosterone climb above the target range or estradiol spike unexpectedly.

The practical takeaway: check testosterone and estradiol at 6 to 8 weeks after adding bupropion to an existing enclomiphene regimen (or vice versa). If testosterone exceeds the upper target or estradiol rises above 40 to 50 pg/mL, a dose reduction of enclomiphene by 25% to 50% is reasonable before rechecking labs at another 4-week interval.

Pharmacodynamic Interaction: Seizure Threshold

This is the interaction that deserves the most clinical attention. Bupropion carries a dose-dependent seizure risk. The FDA label reports an incidence of approximately 0.4% (4 per 1,000) at doses up to 450 mg/day, with the risk climbing sharply above that ceiling (FDA bupropion label). Bupropion's seizure risk led to a temporary market withdrawal in 1986 before dose-titration protocols and the sustained-release formulation reduced event rates (Davidson, 1989, J Clin Psychiatry).

Estrogen-modulating compounds have their own, separate seizure signal. Clomiphene citrate's prescribing information lists seizure as a rare adverse event. A case series published in Epilepsia described new-onset seizures in three women during clomiphene-stimulated ovulation induction cycles, with resolution after drug discontinuation (Tan & Jacobs, 1986). The proposed mechanism involves estradiol fluctuations: estrogen is broadly pro-convulsant, while progesterone is anticonvulsant. Rapid estradiol surges during clomiphene therapy may transiently lower the seizure threshold (Velíšková, 2007).

No study has quantified the additive seizure risk when bupropion and an estrogen receptor modulator are combined. The theoretical concern is real but the absolute risk remains low for patients who have no seizure history and who use bupropion at or below 300 mg/day. Patients with a prior seizure, eating disorder, alcohol withdrawal history, or concurrent use of other threshold-lowering medications (tramadol, theophylline, systemic corticosteroids) carry a higher baseline risk and need individualized risk-benefit discussion before adding enclomiphene.

How Enclomiphene Differs from Racemic Clomiphene

Most published DDI data references racemic clomiphene, which contains both the trans-isomer (enclomiphene) and the cis-isomer (zuclomiphene). Zuclomiphene has estrogenic agonist activity and an elimination half-life measured in weeks, while enclomiphene acts primarily as an estrogen receptor antagonist with a half-life closer to 10 hours (Kaminetsky et al., 2013).

This distinction matters for two reasons. First, the shorter half-life of enclomiphene means any CYP2D6-mediated accumulation from bupropion would reach a new steady state faster, making the interaction window more predictable. Second, the absence of zuclomiphene removes the chronic estrogenic stimulus that may contribute to sustained estradiol elevation and, in theory, prolonged seizure threshold lowering. Enclomiphene alone should produce a cleaner anti-estrogenic profile at the hypothalamic-pituitary axis.

Still, the lack of dedicated interaction studies for the isolated trans-isomer means clinicians should not assume safety from first principles alone. Monitor as if the interaction exists until data prove otherwise.

Monitoring Protocol for Co-Prescribed Patients

A structured monitoring approach reduces risk. The schedule below reflects consensus from the Endocrine Society's clinical practice guideline on testosterone therapy (Bhasin et al., 2018) and standard bupropion prescribing guidance.

Baseline (before starting the second agent):

• Complete metabolic panel including ALT and AST
• Total testosterone, free testosterone (calculated or equilibrium dialysis)
• LH and FSH
• Estradiol (sensitive LC-MS/MS assay preferred)
• CBC with hematocrit
• Document seizure history, eating disorder history, and alcohol use

Week 6 to 8:

• Repeat total testosterone, estradiol, LH, FSH
• Repeat hepatic panel
• Screen for new neurologic symptoms (tremor, myoclonus, headache pattern changes)
• Assess mood response and sexual function

Week 16 to 20 and every 6 months thereafter:

• Full lab panel repeat
• Hematocrit monitoring (enclomiphene-driven testosterone elevation can increase erythropoiesis)
• Seizure risk reassessment if dose changes occur for either drug

If testosterone exceeds 1,100 ng/dL or estradiol rises above 50 pg/mL, reduce the enclomiphene dose first. If bupropion has been recently uptitrated, consider whether the pharmacokinetic interaction is driving the lab shift rather than a change in hypothalamic-pituitary-gonadal axis sensitivity.

Dose Adjustment Considerations

No published dose-adjustment algorithm exists for this drug pair. The recommendations below draw from pharmacokinetic principles and clinical experience with CYP2D6-inhibitor combinations.

Bupropion dose should not exceed 300 mg/day when co-prescribed with enclomiphene. The FDA label already warns against exceeding 450 mg/day in any patient, and the co-prescription of an estrogen modulator adds a second seizure-relevant variable. Keeping bupropion at or below 300 mg/day (typically the SR 150 mg twice-daily formulation) stays well within the lower-risk range documented in post-marketing surveillance (Dunner et al., 1998).

Enclomiphene doses in clinical trials for secondary hypogonadism have ranged from 12.5 mg to 25 mg daily (Wiehle et al., 2014). When bupropion is on board, starting enclomiphene at 12.5 mg daily and titrating based on 6-to-8-week labs is a conservative, defensible strategy. If the patient is already stable on 25 mg of enclomiphene and bupropion is being added, hold the enclomiphene dose and recheck labs at 6 to 8 weeks rather than preemptively reducing.

Other Drug Interactions Relevant to Enclomiphene Patients

Patients on enclomiphene often take additional medications that warrant attention. A few notable interactions:

Tamoxifen. Both tamoxifen and enclomiphene are selective estrogen receptor modulators (SERMs). Co-administration is pharmacologically redundant and may produce additive anti-estrogenic effects. Concurrent use is not standard practice and should prompt a reassessment of the treatment plan.

Aromatase inhibitors (anastrozole, letrozole). Some clinicians combine an aromatase inhibitor with enclomiphene to control estradiol. This combination reduces substrate for estradiol synthesis while simultaneously blocking estrogen receptor feedback. The risk is over-suppression of estradiol below 15 to 20 pg/mL, which can impair bone mineral density, lipid profiles, and libido. Monitor estradiol closely if this combination is used (Loves et al., 2008).

CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir). If CYP3A4 contributes to enclomiphene clearance, strong 3A4 inhibitors could compound the effect of bupropion's CYP2D6 inhibition, creating a "dual metabolic block." Patients on protease inhibitor-based HIV regimens or chronic azole antifungals should have more frequent lab monitoring when enclomiphene is added.

Alcohol. Bupropion's FDA label recommends minimizing alcohol use due to the seizure risk interaction. This applies with equal force when enclomiphene is co-prescribed, and patient counseling should address this directly.

Patient Counseling Points

Prescribers and pharmacists should cover these topics at the time of co-prescription:

Seizure awareness. Patients should understand that both drugs carry a small, independent seizure signal. The combined risk is not well-quantified but is likely additive rather than synergistic. Any new-onset loss of consciousness, involuntary muscle jerking, or unexplained "blackout" episodes require immediate medical evaluation.

Lab compliance. The monitoring schedule works only if patients complete their lab draws. Emphasize that the 6-to-8-week labs are not optional. They detect both the pharmacokinetic interaction (via testosterone and estradiol levels) and potential hepatotoxicity (via ALT/AST).

Alcohol and stimulant use. Both lower the seizure threshold independently. Patients should limit alcohol to two or fewer standard drinks per occasion and should disclose any stimulant use (prescription amphetamines, cocaine, high-dose caffeine) so the prescriber can adjust the risk calculus.

Symptom diary. Encourage patients to track mood, libido, energy, and any neurological symptoms (headaches, tremors, visual disturbances) during the first 8 weeks. Clomiphene-class drugs have been associated with rare visual side effects including blurred vision and scotomata (Purvin, 1995), and bupropion can cause dose-dependent tremor. A symptom diary helps distinguish drug effects from unrelated complaints.

What the Evidence Does Not Yet Show

No randomized controlled trial has evaluated the enclomiphene-bupropion pair specifically. The interaction profile is inferred from bupropion's known CYP2D6 inhibition potency, clomiphene's metabolic pathway data, and pharmacodynamic theory about seizure thresholds and estrogen modulation. This is standard clinical pharmacology reasoning, but it is not the same as a prospective DDI study with measured AUC ratios and Cmax changes.

The Endocrine Society has not issued guidance on SERM-antidepressant co-prescription in men with secondary hypogonadism (Bhasin et al., 2018). The American Urological Association's 2018 guideline on testosterone deficiency similarly does not address this combination (Mulhall et al., 2018).

Until prospective data emerge, the combination is best categorized as "use with monitoring" rather than "avoid." Most patients will tolerate both drugs without incident. The small subset at elevated risk (those with seizure history, hepatic impairment, or polypharmacy involving additional CYP2D6 substrates) requires the tightest surveillance.

Clinicians adding enclomiphene to an existing bupropion regimen should order baseline labs, start at 12.5 mg daily, and recheck testosterone, estradiol, and hepatic markers at 6 to 8 weeks.